Why LH-Surge Control Organises the Whole Field
The central pharmacological problem in stimulated cycles is straightforward to state. As multiple follicles grow, rising oestradiol would, in a natural cycle, trigger an endogenous LH surge and spontaneous ovulation before the oocytes could be retrieved. Every mainstream protocol exists to hold back that surge until final maturation is deliberately triggered. Because of this, the most useful way to teach the protocol landscape is not by drug brand or by cycle-day calendar, but by the suppression mechanism itself. Three mechanisms dominate contemporary practice: pituitary desensitisation with a gonadotrophin-releasing hormone (GnRH) agonist, competitive receptor blockade with a GnRH antagonist, and progesterone-mediated suppression in progestin-primed ovarian stimulation (PPOS).
GnRH-Agonist Protocols
GnRH-agonist protocols suppress the pituitary through sustained receptor stimulation, which after an initial “flare” leads to receptor downregulation and a hypogonadotrophic state before gonadotrophins are introduced. In the classic long protocol, agonist administration begins in the preceding luteal phase, so that by the time stimulation starts the pituitary is desensitised and the endogenous surge is reliably held. Variants include short (flare) and ultra-short schedules that exploit the initial agonist-driven release of endogenous gonadotrophins.
The teaching points are the extended timeline, the deeper and less rapidly reversible suppression, and the fact that final maturation in a fresh agonist cycle is conventionally triggered with human chorionic gonadotrophin (hCG) because the pituitary is desensitised. That last property becomes clinically important when OHSS risk is high, as discussed below.
GnRH-Antagonist Protocols
GnRH-antagonist protocols suppress the pituitary by competitive, immediately reversible blockade of the GnRH receptor, introduced during stimulation once follicles reach a defined size or on a fixed day. Because blockade is rapid in onset and offset, the regimen is shorter, avoids the profound downregulation of the long agonist approach, and preserves the option of triggering final maturation with a GnRH agonist rather than hCG.
In its guideline on ovarian stimulation for IVF/ICSI, first published in 2019–2020 in Human Reproduction Open and updated in 2025, ESHRE issues a strong recommendation favouring the GnRH-antagonist protocol over agonist protocols in the general population, on the basis of a comparable efficacy profile alongside a more favourable safety margin, principally a lower risk of OHSS. For predicted poor responders, ESHRE describes agonist and antagonist approaches as broadly equivalent options rather than ranking one above the other. Clinicians in training should read this as a default-of-choice framing for the general population rather than an absolute rule, since patient phenotype, prior response and unit protocol all bear on selection.
Progestin-Primed Ovarian Stimulation (PPOS)
Progestin-primed ovarian stimulation is a protocol that prevents the premature LH surge by administering an exogenous oral progestin during stimulation, reproducing the surge-suppressing effect that luteal-phase progesterone exerts in the natural cycle. Rather than acting at the GnRH receptor, PPOS relies on progesterone's negative feedback on pituitary LH release, which reviews indexed on PubMed Central describe as a robust means of controlling the preovulatory surge.
Two consequences define how PPOS is taught. First, progestins are given orally, which removes an injection burden and is frequently described in the literature as a practical and cost-conscious feature. Second, early progesterone exposure desynchronises the endometrium from the developing embryo cohort, so a fresh transfer is not appropriate; PPOS is therefore a freeze-all strategy, with all usable embryos cryopreserved for a subsequent frozen embryo transfer. For that reason PPOS sits most naturally in programmes already oriented toward elective cryopreservation, and its rise has paralleled improvements in vitrification and frozen-transfer workflows.
How Ovarian Reserve Markers Individualise Stimulation
Individualised stimulation is the practice of selecting the protocol, gonadotrophin starting dose and trigger strategy according to a predicted ovarian response, rather than applying a single regimen to every patient. The two markers that anchor this prediction are anti-Müllerian hormone (AMH) and the antral follicle count (AFC).
Both AMH and AFC correlate with the size of the recruitable follicle pool, and systematic reviews indexed on PubMed Central report that each predicts poor and high response with broadly similar accuracy; many units use them together, with AFC obtained at baseline ultrasound and AMH from serum. In practical teaching terms, the markers sort patients into anticipated poor, normal and high responders, and that expected category then informs both dose and OHSS-mitigation planning.
The dose implication runs in two directions. For anticipated poor responders, higher starting doses are commonly used, though the marginal yield of escalating dose is limited and is a recognised point of clinical debate. For anticipated high responders, restraint is the safer instinct: lower starting doses reduce the number of follicles driven to maturity and, with it, OHSS exposure. A Cochrane systematic review referenced in the reserve-marker literature concludes that individualising the gonadotrophin starting dose may reduce treatment risks such as OHSS, which is the core educational justification for measuring reserve before prescribing. The principle to convey is that reserve markers are used to calibrate intensity and anticipate risk, not to promise any particular outcome.
Where PCOS and OHSS Risk Sit Within Protocol Selection
Ovarian hyperstimulation syndrome is an iatrogenic condition in which stimulation, and the LH-like activity of an hCG trigger, drive vascular permeability and fluid shifts, with a spectrum from mild discomfort to rare severe presentations. Because risk scales with the number of growing follicles and with peak oestradiol, the high-responder phenotype — prominently women with PCOS, a high AFC or a high AMH — is where prevention strategy concentrates.
Protocol choice is one of the principal levers. Selecting an antagonist protocol keeps open the option of a GnRH-agonist trigger, which induces a short, physiological LH rise instead of the prolonged stimulus of hCG. The 2023 ASRM guideline on prevention and treatment of moderate and severe OHSS supports using a GnRH-agonist trigger to reduce OHSS risk when peak oestradiol is high or multifollicular development is evident. Because an agonist trigger provides limited luteal support, it is characteristically paired with a freeze-all approach and deferred frozen transfer. For PCOS specifically, sources indexed on PubMed Central describe replacing the hCG trigger with an agonist trigger and vitrifying all embryos as a recognised good-practice pattern, alongside conservative dosing and, in some protocols, adjuncts discussed in the guideline literature.
The training synthesis is that PPOS and antagonist protocols both align well with OHSS-conscious, freeze-all pathways for high responders, whereas a fresh long-agonist cycle with an hCG trigger offers less room to defuse a developing high response late in the cycle. None of these assures any particular outcome; they are risk-management principles that a clinician weighs against the individual case.
Monitoring, Triggering and the Wider Cycle
Whatever the suppression method, protocols are steered in real time by serial transabdominal or transvaginal ultrasound and, in many units, serum oestradiol, so that dose can be adjusted and the trigger timed by follicular diameters. ESHRE's guideline devotes substantial attention to monitoring, to the triggering of final maturation and to luteal support, underscoring that a protocol is a framework to be adjusted rather than a fixed script. Downstream, the quality of the retrieved cohort is read through laboratory endpoints; the companion overview of IVF laboratory performance indicators for clinicians sets out how fertilisation, cleavage and blastulation metrics are interpreted once oocytes reach the embryology bench.
For Clinicians Developing Hands-On Protocol Experience
Reading protocol logic is a starting point; applying it — reconciling reserve markers, suppression method, dose and trigger for a specific phenotype — is a practised clinical skill developed under supervision. ATDERA's postgraduate medical-education programmes are designed around that translation from principle to bedside decision. Clinicians who want to build structured, supervised experience across the stimulation-to-laboratory pathway can review the fine-ART Masterclass, delivered with Centrum Clinic in Ankara, which situates protocol selection within the wider assisted-reproduction workflow. Programme details and dates are set out on the programme page.
This article is an educational overview for healthcare professionals and does not constitute clinical or patient guidance. Clinical management should follow current ESHRE and ASRM guidance and local protocols.